UCB
Tracked across 3 events · 50 articles · First seen Jul 13, 2026 · Last active Sep 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: UCB obtained worldwide exclusive license to develop and commercialize ATG-201, expanding its autoimmune disease pipeline. The upfront payment and potential milestones represent a strategic investment.
Jul 13, 2026 · 7 articles
Domestic
On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed…
Impact: UCB joined the MFN pricing agreement, offering drugs at reduced prices to United States — Medicaid. This could impact U.S. sales but secures tariff exemptions.
Aug 18, 2026 · 37 articles
Business
Impact: UCB is a partner that has licensed an Antengene TCE candidate, benefiting from potential pipeline expansion.
Jul 20, 2026 · 6 articles
80
UCB signed drug pricing deal United StatesTrump announces nine new...
60
UCB donated active pharmaceutical ingredients United StatesTrump announces nine new...
ERGEN INTELLIGENCE
Track UCB live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard